If you’ve already registered, please click here to log in to the webcast.

Selecting the right biomarkers is important for success in phase transition of clinical trials. Spatial Phenotyping has increasingly allowed us to select high-quality protein biomarkers that correlate more strongly with patient outcomes. There is a growing need to identify high-quality protein biomarkers to support clinical research, and spatial biology is showing promise in providing these answers.

This webcast will present the use of a 51-plex panel that covers a range of functional and tumor microenvironment-related biomarkers, including lymphoid and myeloid cell markers, tissue biomarkers, antigen presenting cells, and immune checkpoint and activation markers. Analyzing this comprehensive panel of biomarkers identifies cell types that are up or downregulated in different disease states. Further, exploring the spatial relationships between cells uncovers important differences in cell-to-cell interactions and neighborhoods between disease states. These spatial analyses offer a powerful toolkit for discovering key biomarkers in various diseases and treatments.

• What insights can be gained from spatial analysis of tissue?
• What cellular subtypes, neighborhoods, and cell-cell interactions are predictive of response to a targeted therapy and to delineate disease severity?
• Which pathways should we be more deeply interrogating and drugging given their link to disease progression?